Plus Therapeutics: Funding, Investors & Team (Sep 2026)
Plus Therapeutics is dedicated to developing and delivering innovative cell-based therapies to improve the quality and length of life. It is a global, public company engaged in the development and commercialization of stem and regenerative cell therapies for the treatment of cardiovascular disease, reconstructive surgery, and other serious, chronic, and life-threatening conditions. Plus Therapeutics pipeline of candidate drug products includes their lead drug product candidates, RNL and DocePLUS, which are being developed in the U.S. by a dedicated and energetic team of biologists, chemists, engineers, physicians, and other professionals.
Plus Therapeutics has raised $17.6M across 1 funding round on record, the most recent a Grant of $17.6M announced in Aug 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Plus Therapeutics Company Profile and Key Stats
Latest funding round on record: Aug 2022.
Plus Therapeutics Funding Rounds
Plus Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Plus Therapeutics Funding Compared to Other Biotechnology Startups
Plus Therapeutics' latest round of $17.6M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Plus Therapeutics in Biotechnology and Austin
Companies Similar to Plus Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Plus Therapeutics Funding FAQs
What does Plus Therapeutics do?
Plus Therapeutics is dedicated to developing and delivering innovative cell-based therapies to improve the quality and length of life. It is a global, public company engaged in the development and commercialization of stem and regenerative cell therapies for the treatment of cardiovascular disease, reconstructive surgery, and other serious, chronic, and life-threatening conditions. Plus Therapeutics pipeline of candidate drug products includes their lead drug product candidates, RNL and DocePLUS, which are being developed in the U.S. by a dedicated and energetic team of biologists, chemists, engineers, physicians, and other professionals.
How much funding has Plus Therapeutics raised?
Plus Therapeutics has raised $17.6M across 1 round on record. The most recent is a Grant of $17.6M announced in Aug 2022.
When did Plus Therapeutics last raise funding?
Plus Therapeutics' most recent funding round on record is a Grant of $17.6M, announced in Aug 2022.
Who is the CEO of Plus Therapeutics?
Marc Hedrick is listed as CEO at Plus Therapeutics.
Where is Plus Therapeutics headquartered?
Plus Therapeutics is based in Austin, Texas, United States.
How many employees does Plus Therapeutics have?
Plus Therapeutics is in the 11-50 employee band.
How does Plus Therapeutics' funding compare to other Biotechnology startups?
Plus Therapeutics' latest round of $17.6M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Plus Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Plus Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.